

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 223/18, C07C 63/33	A1	(11) International Publication Number: WO 99/52877 (43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/US98/07389 (22) International Filing Date: 14 April 1998 (14.04.98) (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSENBERG, Martin [US/US]; 241 Mingo Road, Royersford, PA 19468 (US). WIDDOWSON, Katherine, Louisa [CA/US]; 1047 Old Valley Forge Road, King of Prussia, PA 19406 (US). (74) Agents: BAUMEISTER, Kirk et al.; Smithkline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: RECEPTOR LIGANDS (57) Abstract Non-antibody multimeric receptor ligands, methods for making and identifying them and their use for agonizing or antagonizing multimeric receptors.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

RECEPTOR LIGANDSRELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/030,391, filed November 5, 1996.

10

FIELD OF THE INVENTION

This invention relates to multimeric receptor ligands, methods for making and identifying them and their use as agonist or antagonists of multimeric biological receptors.

BACKGROUND OF THE INVENTION

Many receptors of the single transmembrane class appear to respond to ligand binding by some form of aggregation. Aggregation can be in the form of homodimerization or homotrimerization in the case of identical receptor subunits or in the form of heterodimerization or heterotrimerization in the case of different receptor subunits. It has become clear in several systems that receptor aggregation is part of the signal for the target cell to respond biologically. See review by Young, P.R. entitled "Protein hormones and their receptors" in *Curr. Opin. Biotech.* 3, 408-421 (1992).

Monoclonal antibodies have been discovered which have agonist activity to the dimeric epidermal growth factor (EGF), tissue necrosis factor (TNF) and growth hormone (GRH) receptors. See Schreiber, A.B. et al., *J. Biol. Chem.* 258, 846-853 (1983), Defize, L.H.K. et al., *EMBO J.* 5, 1187-1992 (1986), Englemann, H. et al., *J. Biol. Chem.* 256, 14497-14504 (1990) and Fuh, G. et al., *Science* 260, 1808-1810 (1992). While not wishing to be bound to any particular theory of receptor activation, it is believed that in all three cases, the monoclonal antibodies, by virtue of possessing two antigen binding sites, were able to bridge two receptor molecules to facilitate aggregation and thus activate them.

5 Receptor-mediated biological functions are implicated in many conditions. Indications for compounds with agonist or antagonist activity towards single transmembrane receptors are numerous.

10 Despite the success of monoclonal antibodies in producing an agonist response in certain dimeric receptors, they are not considered ideal candidates for development of pharmaceutical compositions. Lack of oral bioavailability and a limited serum half-life limit the desirability and efficacy of monoclonal antibodies
15 as pharmaceutical agents. Consequently, a need exists for non-antibody ligands which have agonist or antagonist properties towards dimeric or trimeric receptors.

20 SUMMARY OF THE INVENTION

Accordingly, one aspect of the present invention is a method for agonizing or antagonizing a multimeric receptor comprising contacting the multimeric receptor with a non-antibody multimeric receptor ligand.

25 Another aspect of the invention is a method for identifying agonists and antagonists of multimeric receptors. The method comprises the steps of contacting a multimeric receptor with non-antibody multimeric receptor ligand candidates and selecting ligand
30 candidates which bind to the receptor.

A third aspect of the invention is isolated non-antibody multimeric receptor agonists or antagonists.

A fourth aspect of the invention is a method for making non-antibody multimeric receptor ligands. The
35 method comprises the steps of reacting a bifunctional monomer bound to a solid support with a receptor binding moiety and cleaving the reaction product from the solid support wherein the two functional groups are identical and symmetrically placed after cleavage.

5 DETAILED DESCRIPTION OF THE INVENTION

Aspects of the present invention are non-antibody multimeric receptor agonists or antagonists and a method for agonizing or antagonizing a multimeric receptor by contacting the multimeric receptor with a non-antibody multimeric receptor ligand. A multimeric receptor is a receptor entity which is agonized or antagonized only when two or more subunits of the entity are aggregated on the same cell surface through binding to a common ligand.

15 Multimeric receptors which appear to signal by heterodimerization include granulocyte-macrophage-colony-stimulating factor (GM-CSF) receptor, the interleukins -3, -4, -5, -6, -12 and -13 (IL-3, 4, 5, 6, 12, and 13) receptors, oncostatin M, ciliary neurotropic factor (CNTF) receptor, leukemia inhibitory factor (LIF) receptor, nerve growth factor (NGF) receptor, fibroblast growth factor (FGF) receptor, the interferons α , β and γ (IFN- α , β and γ) receptors and TGF β 1,2 receptor. Heterotrimeric signaling receptors include interleukin-2 20 (IL-2) receptor and tissue necrosis factor (TNF) receptor.


Known multimeric homodimerizing receptors include erythropoietin (EPO) receptor, granulocyte-colony-stimulating factor (G-CSF) receptor, macrophage-colony-stimulating factor (M-CSF) receptor, tissue growth 30 factor α (TGF α) receptor, epidermal growth factor (EGF) receptor, neu receptor, growth hormone (GRH) receptor, prolactin receptor, placental lactogen receptor, stem cell factor receptor (c-kit), tissue necrosis factor α and β (TNF α , β) receptors, fas receptor, CD40 receptor and CD27 receptor.

The non-antibody multimeric receptor ligand of the present invention serves as the common ligand through which two or more multimeric receptor subunits 40 aggregate. The multimeric receptor ligand includes a

- 5 spacer which is substituted with two or more receptor binding moieties.


The spacer can be any molecule having a di- or trisubstituted center capable of substitution with the receptor binding moieties. Preferably, the spacer
10 provides for spatial separation and steric orientation of the receptor binding moieties which is sufficient to effectively induce aggregation while not sterically preventing such association. Most preferably, the
15 spacer will provide spatial separation and steric orientation of the binding moieties which mimic the binding moieties of the natural ligand.

Exemplary disubstituted spacers include compounds represented by the formula (I):




wherein:


5 A is independently N, O, S, dithio, carbonyl,



Z is independently N, O, S or carbonyl;

R is independently *d*- or *l*-amino acid; alkyl of 1 to 10 carbons; *cis*, *trans*-2-butenyl; *cis*, *trans*-1,2-cyclopropyl; *cis*, *trans*-1,2-cyclobutyl; *cis*, *trans*-1,3-cyclobutyl; *cis*, *trans*-1,3-cyclopentyl; *cis*, *trans*-1,2-cyclopentyl; *cis*, *trans*-1,2-cyclohexyl; *cis*, *trans*-1,3-cyclohexyl; *cis*, *trans*-1,4-cyclohexyl; *endo*, *exo*-2,3-norbornane; 1,5-naphthyl; 2,6-naphthyl; 1,8-anthrylene;
 15 1,5-anthrylene; 2,6-anthrylene;






where

- 10 X is independently N, O or S;
 M is independently C or N;
 p is 0, 1, 2, or 3; and
 m is 0 or 1; and
 n is 0, 1, 2 or 3.

- 15 Preferred compounds of formula (I) are those where

R is




- 5 Exemplary trisubstituted spacers include compounds represented by the formula (II):

Z

(R)_n




10



wherein:


Q is C; N; B; 1,3,5-phenyl; 1,3,5-cyclohexyl;

1,3,5-triazinyl;



15

or



where J is independently H or alkyl of 1 to 10 carbons; and


Z is independently N, O, S or carbonyl;


20

R is independently d- or l-amino acid; alkyl of 1 to 10 carbons; *cis*, *trans*-2-butenyl; *cis*, *trans*-1,2-cyclopropyl; *cis*, *trans*-1,2-cyclobutyl; *cis*, *trans*-1,3-

- 5 cyclobutyl; *cis*, *trans*-1,3-cyclopentyl; *cis*, *trans*-1,2-cyclopentyl; *cis*, *trans*-1,2-cyclohexyl; *cis*, *trans*-1,3-cyclohexyl; *cis*, *trans*-1,4-cyclohexyl; *endo*, *exo*-2,3-norbornane; 1,5-naphthyl; 2,6-naphthyl; 1,8-anthrylene; 1,5-anthrylene; 2,6-anthrylene;

10





where

X is independently N, O or S;

M is independently C or N;



10 p is 0, 1, 2, or 3; and

m is 0 or 1; and

n is 0, 1, 2 or 3.

Preferred compounds of formula (II) are those where

R is



and

20 One skilled in the art could determine the required spatial separation and steric orientation of the receptor binding moieties through X-ray crystallographic data for receptor entities with and without bound natural ligand. For example, the X-ray crystal structures of HGH (a 4-helix bundle protein) complexed

5 with its homodimeric receptor, HGH binding protein
(HGHBP), have been published by Fuh et al. in *Science*
256, 1677-1680 (1992). The two HGHBP molecules of the
receptor bind HGH with considerable C₂ symmetry.
Analysis of the superimposition of the crystal structure
10 of HGH•(HGHBP)² with an identical crystal structure,
where the identical crystal structure has been rotated
through a C₂ axis to maximize the overlap of the binding
proteins, provides vectors for points of attachment for
the receptor binding moieties. Design of spacer
15 molecules which contain these vectors could be aided by
conducting three-dimensional compound database searches
using programs such as CAVEAT (Regents of the University
of California) or SYBYL 3-D (Tripos Associates Inc.)
This process could yield both C₂ symmetric and non-C₂
20 symmetric spacers.

The spacers derived from examination of HGH may be
useful in designing ligands for other hematopoietic
receptors, since it is known that dimeric receptor
ligands share common structural features which lead to
25 aggregation of the receptor subunits. It is expected
that this method could also be generalized to other
receptor-ligand complexes when their crystal structures
become available.

The receptor binding moieties which attach to these
30 spacers can be either peptides or small molecules from a
natural or synthetic source. The peptide sequences
could be chosen from but not limited to linear and
cyclic sequences known to be important for binding of
hematopoietic proteins to their receptors. Particularly
35 interesting are those sequences found in helices one and
four of the four α -helix bundle class of protein
ligands, since these helices are important for binding
and seem optimally situated for dimerization. Also, the
helices, unlike the loop regions of these receptors, are
40 very similar in orientation throughout this class of

5 proteins. The identity of the possible small molecules could be chosen from but not limited to agonists and antagonists derived from database screens and peptide mimetics.

10 The receptor binding moieties of the non-antibody multimeric receptor ligands of the present invention can be identical, yielding homomultimeric compounds, or they can be different, yielding heteromultimeric compounds. In general, non-antibody multimeric receptor ligands could be synthesized by reacting a bifunctional monomer
15 bound to a solid support with a receptor binding moiety to form a reaction product followed by cleaving the reaction product from the solid support, wherein the two functional groups are identical and symmetrically placed after cleavage.

20 Those of ordinary skill in this art would recognize that any single peptide or small organic molecule could be coupled to the spacer substitution centers to provide homomultimeric receptor ligand candidates.

Heteromultimeric compounds can be produced through
25 combinatorial chemistry methods in which a library of compounds is synthesized. Combinatorial synthetic methods known to those skilled in the art can produce library members simultaneously as a mixture or individually. Diverse sets of biopolymers such as
30 peptides containing naturally occurring and non-naturally occurring α - and β -amino acids, oligonucleotides and oligosaccharides as well as small organic molecules can be produced.

Linear peptide and oligonucleotide libraries can be
35 produced by synthesis on a solid support, such as synthesis beads, followed by cleavage from their supports. Solution synthetic methods could also be employed.

Small organic molecule library members are built up
40 on a core structure template. The core structure is

5 derivatized through a series of synthetic steps to
produce a library containing a discrete number of
independently variable substituents, functional groups
or structural elements. Reaction conditions are
selected such that each derivatized core structure is
10 different from the others. Methods for derivatizing
core structures are disclosed in U.K. Patent Application
No. 9325621.2, which is incorporated herein by
reference.

Non-antibody heteromultimeric receptor ligand
15 candidates are provided by substitution of library
members onto the spacer. The spacer is coupled to a
solid support such as a synthesis bead and the
combinatorial library members are built out from the
substitution centers present on the spacer. After
20 library synthesis is complete, the resulting ligand
candidates are cleaved from the support by techniques
well known to those skilled in the art.

Another aspect of the present invention is a method
for identifying agonists and antagonists of multimeric
25 receptors and the multimeric receptor ligands identified
thereby. In the method, a multimeric receptor is
contacted with non-antibody multimeric receptor ligand
candidates. Ligand candidates which bind to the
multimeric receptor are selected by receptor binding
30 assays well known to those skilled in the art.

In general, a target receptor in isolated,
immobilized or cell-bound form is contacted with a
plurality of receptor ligand candidates and those
candidates which bind to and interact with the receptor
35 are selected. Binding or interaction can be measured
directly by using radioactively labeled ligand
candidates or by measuring any second messenger effect
resulting from the interaction or binding of the ligand
candidate. Alternatively, the ligand candidates can be
40 subjected to competitive binding assays in which a known
receptor ligand, labeled preferably with an analytically

5 detectable reagent, most preferably radioactivity, is included with the ligand candidates and a candidate's ability to inhibit the binding of the labeled ligand is measured.

Positive multimeric receptor ligand binding
10 candidates are screened for biological function by any one of the receptor function assays well known to those skilled in the art. It is expected that a positive ligand binding candidate will exhibit agonist or antagonist activity in receptor function assays.

15 Any agonist or antagonist compounds identified can be isolated by affinity chromatography. Other isolation techniques for multimeric small organic molecules include labeling the receptor binding moieties as they are being synthesized with coding agents such as
20 oligonucleotides and peptides or tagging the moieties with structurally related molecules that can be analyzed by electron capture capillary gas chromatography.

A non-limiting specific competitive binding assay example follows.

25

COMPETITIVE BINDING ASSAY EXAMPLE A

Tissue containing the appropriate target receptor is homogenized, filtered through cheesecloth and centrifuged at 1500 x g for 10 minutes. Alternatively,
30 cell membrane preparations from cells transfected or transformed with the target receptor gene may be employed. The supernatant is decanted and the pellet is resuspended in an appropriate incubation buffer, e.g., 75 mM Tris-HCl, pH 7.4 containing 12.5 mM MgCl₂ and 1.5
35 mM EDTA. Membranes equivalent to 100 µg protein are incubated with 50 pmol radiolabeled receptor ligand and an appropriate amount of the ligand binding candidate in a total volume of 500 µl for 1 hr at 37°C. The binding reaction is terminated by dilution with the addition of
40 5 ml of cold incubation buffer and the bound tracer is

5 separated from free by filtration on Whatman GF/C filter paper. The filter paper is washed several times with cold incubation buffer and then counted to determine the amount of bound ligand. The presence of a competing ligand is evidenced by a reduction in binding of the
10 radiolabeled receptor ligand relative to a control lacking the addition of ligand binding candidate.


The present invention will now be described with reference to the following specific, non-limiting
15 Examples 1 and 2. The diacids produced by the methods of Examples 1 and 2 and other diacids within the scope of the invention can serve as a spacer by attachment through an amide or ester bond. They can also be reduced to the corresponding alcohols using a reducing
20 agent such as borane, LiAlH_4 or diisobutylaluminum hydride; this alcohol can be converted to a leaving group using mesyl chloride, triphenylphosphine and CCl_4 or tosyl chloride. This leaving group can be used to attach the linker to the binding moieties through an
25 ether, amine, sulfide or hydrocarbon linkage. The diamines produced can be attached to the binding moieties through an amide, urea, carbamate or amine linkage. These diacids and diamines can be elaborated further to create other linkers or attached to a resin
30 used in creating combinatorial libraries.

5

EXAMPLE 1**Synthesis of the Disubstituted Spacer 4,6-Dicarboxyiminodibenzyl and 4,6-Diaminoiminodibenzyl**

The synthetic steps are outlined in Scheme 1 below.

10

Scheme 1

a) *n*-butyllithium, CO₂; b) CH₂N₂, ethyl ether; c) ClCOCOCl, ethyl ether; d) CS₂, AlCl₃; e) H₂O₂, OH⁻; f) diphenylphosphoryl azide, triethylamine, *t*-butanol; g) trifluoroacetic acid

15

The monoester **2** is available in two steps from iminodibenzyl **1** (available from Aldrich Chemical Co., Milwaukee, WI.). The iminodibenzyl is first dilithiated with two equivalents of an alkyl lithium, such as *n*-butyllithium, to form the dianion which is subsequently treated with carbon dioxide to form the carboxylic acid. This monocarboxylic acid can then be esterified by standard techniques, such as diazomethane in ether. The monoester **2** can be acylated at the 4-position by a two step procedure. The iminodibenzyl **2** is first treated with oxalyl chloride to form the amide; this intermediate cyclizes to the α -ketoamide upon treatment with a Lewis acid such as AlCl₃, TiCl₄ or FeCl₃. The α -ketoamide **3** can be converted to the diacid by treatment with an oxidizing agent such as H₂O₂ or NaIO₄ and hydrolysis with hydroxide anion (Hess, B.A. et al. J.

30

- 5 Am. Chem. Soc. 91, 1672 (1969)). The diacid can also be converted to the diamine using standard Curtius conditions (diphenylphosphoryl azide and triethylamine or NaN_3 and ClCOCOC1) and the *t*-butyl carbamate produced can be hydrolyzed with trifluoroacetic acid.


10

EXAMPLE 2

Synthesis of the Disubstituted Spacer *trans*-2,6-Dicarboxydecalin and *trans*-2,6-Diaminodecalin

The synthetic steps are outlined in Scheme 2 below.

15

Scheme 2

20

- a) i) lithium diisopropylamide, phenylselenenyl chloride; ii) *m*-chloroperoxybenzoic acid, triethylamine; b) lithium tri-*sec*-butylborohydride; c) Cl_3CCN , heat; d) H_2 , Pd; e) NaOH; f) $\text{CH}_3\text{O}_2\text{CCl}$, pyridine; g) Tebbe reagent, heat; h) H_2 , Pd; i) lithium diisopropylamide, O_3 ; j) AgO

25

The diol 7 is synthesized in two steps from *trans*-1,5-decalindione (available from Aldrich Chemical Co.,

5 Milwaukee, WI). The first-step conversion to the α,β -unsaturated ketones involves conversion to the α -phenyl selenide using a sequential addition of a strong base, such as lithium diisopropylamide or bis[trimethylsilyl]amide, and phenylselenenyl chloride, 10 oxidation of the selenium using hydrogen peroxide or *m*-chloroperoxybenzoic acid followed by a quench of the oxidant and basic elimination. The α,β -unsaturated ketones are then reduced to the corresponding axial alcohols using a bulky hydride, such as L-Selectride® 15 (1.0 M lithium tri-*sec*-butylborohydride in tetrahydrofuran) or K-Selectride® (1.0 M potassium tri-*sec*-butylborohydride in tetrahydrofuran), which prefer equatorial attack. Intermediate 7 is then converted to the desired diamine by conversion to the corresponding 20 trichloroimidate followed by rearrangement to the transposed allylic amide (Overman, L. J. Am. Chem. Soc. 98, 2901-2910 (1976)). The allylic amide is then reduced to the amide by hydrogenation using Pd, Wilkinson's catalyst (tris[triphenylphosphine]rhodium[1] 25 chloride) or Pt as a catalyst and the amide is hydrolyzed using basic hydrolysis such as NaOH, KOH or LiOOH to form the diamine 8. The diol 7 can also be converted to the diacid 10 in five steps. The carbonate is formed using methylchloroformate and a base such as 30 pyridine or triethylamine. The carbonate is then methylenated using Tebbe reagent and the enol ether undergoes an allylic rearrangement. The ester is then hydrogenated using Pd, Wilkinson's catalyst or Pt as a catalyst to form 9. The ester is then enolized using a 35 strong base such as lithium diisopropylamide or sodium bis[trimethylsilyl]amide and the enolate is cleaved with ozone. The dialdehyde produced is treated with silver oxide to form the diacid.

5 The present invention may be embodied in other
specific forms without departing from the spirit or
essential attributes thereof and, accordingly, reference
should be made to the appended claims, rather than to
the foregoing specification, as indicating the scope of
10 the invention.

5

CLAIMS

1. A method for agonizing or antagonizing a multimeric receptor comprising contacting the multimeric receptor with a non-antibody multimeric receptor ligand.

10 2. The method of claim 1 wherein the multimeric receptor is a dimeric receptor.

3. The method of claim 2 wherein the dimeric receptor is homodimeric.

4. The method of claim 3 wherein the non-antibody multimeric receptor ligand is homodimeric.

15 5. The method of claim 2 wherein the dimeric receptor is heterodimeric.

6. The method of claim 5 wherein the non-antibody multimeric receptor ligand is heterodimeric.

20 7. The method of claim 2 wherein the dimeric receptor is a hematopoietic growth factor receptor.

8. The method of claim 2 wherein the dimeric receptor is erythropoietin receptor, granulocyte-colony-stimulating factor receptor, macrophage-colony stimulating factor receptor, tissue growth factor α receptor, epidermal growth factor receptor, neu receptor, growth hormone receptor, prolactin receptor, placental lactogen receptor, stem cell factor receptor, tissue necrosis factor α receptor, tissue necrosis factor β receptor, *fas* receptor, CD40 receptor or CD27 receptor.

30


9. The method of claim 2 wherein the dimeric receptor is platelet-derived growth factor receptor, insulin receptor, insulin-like growth factor-1 receptor, insulin-like growth factor-2 receptor or relaxin receptor.

35

10. The method of claim 2 wherein the dimeric receptor is granulocyte-macrophage colony stimulating factor receptor, interleukin-3 receptor, interleukin-5 receptor, interleukin-6 receptor, oncostatin M receptor, ciliary neurotropic factor receptor, leukemia inhibitory


40

- 5 factor receptor, nerve growth factor receptor, fibroblast growth factor receptor, interleukin-4 receptor, interleukin-13 receptor, interferon α receptor, interferon β receptor, interferon γ receptor, TGF β 1,2 receptor or interleukin-12 receptor.
- 10 11. The method of claim 1 wherein the multimeric receptor is a trimeric receptor.
12. The method of claim 11 wherein the trimeric receptor is heterotrimeric.
13. The method of claim 12 wherein the trimeric
15 receptor is interleukin-2 receptor.
14. The method of claim 12 wherein the trimeric receptor is tissue necrosis factor receptor.
15. A method for identifying agonists and antagonists of multimeric receptors comprising the steps
20 of:
- a) contacting a multimeric receptor with non-antibody multimeric receptor ligand candidates; and
- b) selecting ligand candidates which bind to the receptor.
- 25 16. Multimeric receptor ligands identified by the method of claim 15.
17. Isolated non-antibody multimeric receptor agonists.
18. Isolated non-antibody multimeric receptor
30 antagonists.
19. The isolated non-antibody multimeric receptor agonists or antagonists of claims 17 or 18 comprising a disubstituted spacer having the formula (I):




5 wherein:


A is independently N, O, S, dithio, carbonyl,



Z is independently N, O, S or carbonyl;

R is independently *d*- or *l*-amino acid; alkyl of 1
 10 to 10 carbons; *cis*, *trans*-2-butenyl; *cis*, *trans*-1,2-
 cyclopropyl; *cis*, *trans*-1,2-cyclobutyl; *cis*, *trans*-1,3-
 cyclobutyl; *cis*, *trans*-1,3-cyclopentyl; *cis*, *trans*-1,2-
 cyclopentyl; *cis*, *trans*-1,2-cyclohexyl; *cis*, *trans*-1,3-
 cyclohexyl; *cis*, *trans*-1,4-cyclohexyl; *endo*, *exo*-2,3-
 15 norbornane; 1,5-naphthyl; 2,6-naphthyl; 1,8-anthrylene;
 1,5-anthrylene; 2,6-anthrylene;






where

- 10 X is independently N, O or S;
 M is independently C or N;
 p is 0, 1, 2, or 3; and
 m is 0 or 1; and
 n is 0, 1, 2 or 3.

- 15 20. The isolated non-antibody multimeric receptor agonists or antagonists of claim 19 wherein R is



21. The isolated non-antibody multimeric receptor agonists or antagonists of claims 17 or 18 comprising a trisubstituted spacer having the formula (II):

Z



 $(R)_n$
$$10 \quad \text{--- Z --- (R)}_n \text{--- Q --- (R)}_n \text{--- Z ---}$$

(II)


wherein:

Q is C; N; B; 1,3,5-phenyl; 1,3,5-cyclohexyl;

1,3,5-triazinyl;



or




where J is independently H or alkyl of 1 to 10 carbons; and


Z is independently N, O, S or carbonyl;

20 R is independently d- or l-amino acid; alkyl of 1 to 10 carbons; *cis*, *trans*-2-butenyl; *cis*, *trans*-1,2-cyclopropyl; *cis*, *trans*-1,2-cyclobutyl; *cis*, *trans*-1,3-

- 5 cyclobutyl; *cis*, *trans*-1,3-cyclopentyl; *cis*, *trans*-1,2-cyclopentyl; *cis*, *trans*-1,2-cyclohexyl; *cis*, *trans*-1,3-cyclohexyl; *cis*, *trans*-1,4-cyclohexyl; *endo*, *exo*-2,3-norbornane; 1,5-naphthyl; 2,6-naphthyl; 1,8-anthrylene; 1,5-anthrylene; 2,6-anthrylene;

10





where

X is independently N, O or S;


M is independently C or N;

10 p is 0, 1, 2, or 3; and


m is 0 or 1; and

n is 0, 1, 2 or 3.

22. The isolated non-antibody multimeric receptor agonists or antagonists of claim 21 wherein R is



23. The isolated non-antibody multimeric receptor agonists or antagonists of claim 21 wherein Q is N;



1,3,5-phenyl and

24. A method for making non-antibody multimeric receptor ligands comprising the steps of:

20 a) reacting a bifunctional monomer bound to a solid support with a receptor binding moiety to form a reaction product; and

- 5 b) cleaving the reaction product from the solid support, wherein the two functional groups are identical and symmetrically placed after cleavage.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 223/18; C07C 63/33

US CL :540/590, 591; 562/488; 564/155

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 540/590, 591; 562/488; 564/155

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE STRUCTURE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,361,716 A (PARHAM) 02 January 1968, entire document	1-24
X	US 3,271,365 A (PARHAM) 06 September 1966, entire document	1-24



Further documents are listed in the continuation of Box C.



See patent family annex.

* *A* *B* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *Z*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	---	--------------------------	--

Date of the actual completion of the international search

21 JULY 1998

Date of mailing of the international search report

01 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MATTHEW V. GRUMBLING

Telephone No. (703) 308-1235

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.